Sareum Holdings - SDC-1801’s clinical plan modified

23.11.21 12:52
Edison Investment Research

Sareum’s lead asset SDC-1801 is inching closer to completing its preclinical toxicology studies, although the decision to pursue a capsule alternative to the original suspension formulation, at the cost of a further delay in the clinical trial application (CTA) filing (now expected mid-2022), comes as a surprise. Management asserts that the new formulation adds value to the programme (removing the need to develop capsules at a later stage) and is supported by £4.6m of funds raised in calendar Q221/Q321. While we see merits in the strategy, continued delays may concern the market. Encouragingly, out-licensed asset, SRA737, seems to be gaining traction after Sierra Oncology’s decision to reassess it in combination with other targeted therapies. We expect that the next few months will be crucial for Sareum.

hier klicken zur Chartansicht

Aktuelle Kursinformationen mehr >
Kurs Vortag Veränderung Datum/Zeit
0,066 € 0,068 € -0,002 € -2,94% 03.12./22:00
ISIN WKN Jahreshoch Jahrestief
GB00B02RFS12 A0EALG 0,14 € 0,017 €
Handelsplatz Letzter Veränderung  Zeit
Frankfurt 0,066 € -2,94%  03.12.21
Berlin 0,066 € -6,38%  03.12.21
Stuttgart 0,063 € -10,00%  03.12.21
  = Realtime
Aktien des Tages

Jetzt für den kostenfreien Newsletter "Aktien des Tages" anmelden und keinen Artikel unseres exklusiven Labels AC Research mehr verpassen.

Das Abonnement kann jederzeit wieder beendet werden.

Meistgelesene Artikel
Aktuelle Diskussionen
Es ist noch kein Thema vorhanden.
RSS Feeds

Bitte warten...